Vol 10, No 4 (2021)
Research paper
Published online: 2021-05-31

open access

Page views 687
Article views/downloads 547
Get Citation

Connect on Social Media

Connect on Social Media

Patterns of drug use among type 2 diabetic patients with comorbidities attending a tertiary centre in Lagos Nigeria

Adedunni Wumi Olusanya1, Oluwarotimi Bolaji Olopade, Ifedayo Adeola Odeniyi, Olufemi Adetola Fasanmade
Clin Diabetol 2021;10(4):342-348.


Introduction – Diabetes care involves the use of drugs to control hyperglycaemia and treatment of comorbid disorders in order to prevent cardiovascular morbidity and other complications. This study investigated patterns of comorbidities and drug use among diabetic patients at a tertiary centre in Lagos, Nigeria. Method – This was a cross-sectional study carried out among 216 patients with type 2 DM attending Diabetes Clinic of a tertiary centre. Data was captured by using a questionnaire which documented biodata, number of comorbidities, number and combination of drugs for each participant and analysed using SPSS version 18. Results – Comorbidities were present among 215 out of 216 (99.54%) participants and hypertension and dyslipidaemia were the most common comorbid disorders. The number of pills consumed per patient ranged from 1 to10 with a mean of 4.78± 1.73 and 57.4% were on 5 pills or more. Fixed-dose combination was used in 37 (17.1%) of the patients. Majority of the patients were on metformin as monotherapy or in combination therapy. Antihypertensive most prescribed were renin-angiotensin system (RAS) blockers which was prescribed in 73% of participants. Antiplatelet drugs were used for both primary and secondary prevention of CVDs. Statin was used in less than 50% of the population. Double RAS blockade was also observed in 6% of participants. Conclusions – Comorbidities were common in the diabetic population. Pill load was high but appropriate in most patients. Statin uptake was suboptimal while there was increased uptake of antiplatelet drugs among participants.

Article available in PDF format

View PDF Download PDF file


  1. Skyler JS, Bakris GL, Bonifacio E, et al. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017; 66(2): 241–255.
  2. Diabetes atlas 9th ed. International Diabetes Federation. Brussels. 2019.
  3. Uloko AE, Musa BM, Ramalan MA, et al. Prevalence and Risk Factors for Diabetes Mellitus in Nigeria: A Systematic Review and Meta-Analysis. Diabetes Ther. 2018; 9(3): 1307–1316.
  4. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: . Diabetes Care. 2019; 42(Suppl 1): S90–S9S102.
  5. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on The Comprehensive Type 2 Diabetes Management Algorithm - 2019 Executive Summary. Endocr Pract. 2019; 25(1): 69–100.
  6. Peron EP, Ogbonna KC, Donohoe KL. Antidiabetic medications and polypharmacy. Clin Geriatr Med. 2015; 31(1): 17–27, vii.
  7. Patel TK, Patel PB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol. 2018; 74(6): 819–832.
  8. Clinical Practice Guidelines for Diabetes Management in Nigeria Diabetes Association of Nigeria. Nigeria 2013.
  9. Engel J, Damen NL, van der Wulp I, et al. Adherence to Cardiac Practice Guidelines in the Management of Non-ST-Elevation Acute Coronary Syndromes: A Systematic Literature Review. Curr Cardiol Rev. 2017; 13(1): 3–27.
  10. Hageman D, Pesser N, Gommans LNM, et al. Limited Adherence to Peripheral Arterial Disease Guidelines and Suboptimal Ankle Brachial Index Reliability in Dutch Primary Care. Eur J Vasc Endovasc Surg. 2018; 55(6): 867–873.
  11. Ekoru K, Doumatey A, Bentley AR, et al. Type 2 diabetes complications and comorbidity in Sub-Saharan Africans. EClinicalMedicine. 2019; 16: 30–41.
  12. Alwhaibi M, Balkhi B, Alhawassi TM, et al. Polypharmacy among patients with diabetes: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia. BMJ Open. 2018; 8(5): e020852.
  13. Noale M, Veronese N, Cavallo Perin P, et al. Polypharmacy in elderly patients with type 2 diabetes receiving oral antidiabetic treatment. Acta Diabetol. 2016; 53(2): 323–330.
  14. Adisa R, Fakeye TO. Effect of number and type of antidiabetes medications on adherence and glycemia of ambulatory type 2 diabetes patients in southwestern Nigeria. Pharm Pract (Granada). 2013; 11(3): 156–165.
  15. Geitona M, Latsou D, Toska A, et al. Polypharmacy and Adherence Among Diabetic Patients in Greece. Consult Pharm. 2018; 33(10): 562–571.
  16. Balkhi B, AlQahtani N, Alwhaibi M, et al. Prevalence and Factors Associated With Polypharmacy Use Among Adult Patients in Saudi Arabia. J Patient Saf. 2017 [Epub ahead of print].
  17. World Health Organization (WHO). World Health Organization Technical Report; Medication Safety in Polypharmacy World Health Organization, Geneva, Switzerland; 2019.
  18. Bolen S, Tseng E, Hutfless S, et al. Diabetes Medications for Adults With Type 2 Diabetes: An Update. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016. indexed in PubMed: 27227214.
  19. Moreno Juste A, Menditto E, Orlando V, et al. Treatment Patterns of Diabetes in Italy: A Population-Based Study. Front Pharmacol. 2019; 10: 870.
  20. Nishimura R, Kato H, Kisanuki K, et al. Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. BMJ Open. 2019; 9(3): e025806.
  21. Fadare J, Olamoyegun M, Gbadegesin BA. Medication adherence and direct treatment cost among diabetes patients attending a tertiary healthcare facility in Ogbomosho, Nigeria. Malawi Med J. 2015; 27(2): 65–70.
  22. Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2016; 18(4): 333–347.
  23. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311(5): 507–520.
  24. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000; 321(7274): 1440–1444.
  25. Jennings DL, Kalus JS, Coleman CI, et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med. 2007; 24(5): 486–493.
  26. Ferrières J, Gorcyca K, Iorga ŞR, et al. Lipid-lowering Therapy and Goal Achievement in High-risk Patients From French General Practice. Clin Ther. 2018; 40(9): 1484–1495.e22.